PMID- 11085322
OWN - NLM
STAT- MEDLINE
DCOM- 20060104
LR  - 20190616
IS  - 0077-8923 (Print)
IS  - 0077-8923 (Linking)
VI  - 914
DP  - 2000 Sep
TI  - Correlation between 5-HT content and uptake site density following (S)-MDMA and 
      dexfenfluramine-induced depletion, and with neuroprotection by the glycine 
      site-specific NMDA antagonist ACEA 1021.
PG  - 208-14
AB  - 3,4-Methylenedioxymethamphetamine (MDMA) and fenfluramine are amphetamine 
      analogues that both cause long-term depletion of serotonin (5-HT) and 5-HT uptake 
      sites in brain tissue. Depletion caused by these amphetamines is commonly 
      measured by labeling 5-HT uptake sites using 3H-paroxetine combined with 
      autoradiography or, alternatively measuring the concentration of 5-HT in tissue 
      using high-performance liquid chromatography (HPLC). A close correlation between 
      the 5-HT concentration measured in micropunch samples and the density of 
      3H-paroxetine-labeled 5-HT uptake sites measured in corresponding 20 micron 
      coronal slices was determined (R2 = 0.92). These methods combined demonstrated 
      that the glycine-site specific NMDA antagonist ACEA 1021 (4 x 30 mg/kg, i.p., 2 
      hourly) given 30 minutes before (S)-MDMA (4 x 10 mg/kg, i.p., 2 hourly) was able 
      to prevent the depletion of both 5-HT content and uptake site density but unable 
      to prevent the depletion of 5-HT content and uptake site density caused 
      dexfenfluramine (4 x 15 mg/kg, i.p., 2 hourly).
FAU - Russell, B R
AU  - Russell BR
AD  - Department of Pharmacology, School of Medical Sciences, University of Otago, 
      Dunedin, New Zealand.
FAU - Laverty, R
AU  - Laverty R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Ann N Y Acad Sci
JT  - Annals of the New York Academy of Sciences
JID - 7506858
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Quinoxalines)
RN  - 0 (Serotonin Agents)
RN  - 10028-17-8 (Tritium)
RN  - 333DO1RDJY (Serotonin)
RN  - 3Z3037LJTC (licostinel)
RN  - 41VRH5220H (Paroxetine)
RN  - E35R3G56OV (Dexfenfluramine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Animals, Newborn
MH  - Brain/anatomy & histology/*drug effects/metabolism
MH  - Brain Chemistry/drug effects
MH  - Dexfenfluramine/*pharmacology
MH  - Drug Interactions
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Neuroprotective Agents/*pharmacology
MH  - Paroxetine/pharmacokinetics
MH  - Quinoxalines/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Serotonin/*metabolism/pharmacokinetics
MH  - Serotonin Agents/*pharmacology
MH  - Tritium/pharmacokinetics
EDAT- 2000/11/21 00:00
MHDA- 2006/01/05 09:00
CRDT- 2000/11/21 00:00
PHST- 2000/11/21 00:00 [pubmed]
PHST- 2006/01/05 09:00 [medline]
PHST- 2000/11/21 00:00 [entrez]
AID - 10.1111/j.1749-6632.2000.tb05197.x [doi]
PST - ppublish
SO  - Ann N Y Acad Sci. 2000 Sep;914:208-14. doi: 10.1111/j.1749-6632.2000.tb05197.x.